# A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation

> **NCT06990711** · PHASE1 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 30 (estimated)

## Conditions studied

- Antibody Mediated Rejection of Lung Transplant

## Interventions

- **DRUG:** Siltuximab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06990711
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-06
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06990711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06990711, "A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06990711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*